These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 9295927)

  • 21. Calcium channel blockers and coronary heart disease.
    Inzitari M; Di Bari M; Marchionni N
    Aging Clin Exp Res; 2005 Aug; 17(4 Suppl):6-15. PubMed ID: 16640169
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Endothelium, atherosclerosis and calcium channel blockers.
    Biswas TK
    J Indian Med Assoc; 2003 Jul; 101(7):428-31. PubMed ID: 14748381
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Effects of calcium channel blockers in atherosclerosis and cardiovascular event and oxidative vascular damage].
    Fujino T; Sumitomo K; Hasebe N; Kikuchi K
    Clin Calcium; 2004 Jan; 14(1):119-27. PubMed ID: 15576967
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Calcium antagonists and atherosclerosis].
    Pohjola-Sintonen S; Heikkilä J
    Duodecim; 1991; 107(17):1420-3. PubMed ID: 1365370
    [No Abstract]   [Full Text] [Related]  

  • 25. Lercanidipine: short plasma half-life, long duration of action and high cholesterol tolerance. Updated molecular model to rationalize its pharmacokinetic properties.
    Herbette LG; Vecchiarelli M; Sartani A; Leonardi A
    Blood Press Suppl; 1998; 2():10-7. PubMed ID: 9850437
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Calcium channel blockers and atherosclerosis].
    Hirata K; Yokoyama M
    Clin Calcium; 2004 Jan; 14(1):128-32. PubMed ID: 15576968
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A development of atheromatous plaque is restricted by characteristic arterial wall structure at the carotid bifurcation.
    Hori E; Hayashi N; Hamada H; Masuoka T; Kuwayama N; Hirashima Y; Origasa H; Ohtani O; Endo S
    Surg Neurol; 2008 Jun; 69(6):586-90; discussion 590-1. PubMed ID: 18261781
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Calcium concentration of individual coronary calcified plaques as measured by multidetector row computed tomography.
    Moselewski F; O'Donnell CJ; Achenbach S; Ferencik M; Massaro J; Nguyen A; Cury RC; Abbara S; Jang IK; Brady TJ; Hoffmann U
    Circulation; 2005 Jun; 111(24):3236-41. PubMed ID: 15956133
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Is it wise to restrict fat in the diets of children?
    Olson RE
    J Am Diet Assoc; 2000 Jan; 100(1):28-32. PubMed ID: 10645998
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of calcium channel blockers and angiotensin-converting enzyme inhibitors after cardiac transplantation.
    Rockx MA; Haddad H
    Curr Opin Cardiol; 2007 Mar; 22(2):128-32. PubMed ID: 17284992
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Age-related changes in plaque composition: a study in patients suffering from carotid artery stenosis.
    van Oostrom O; Velema E; Schoneveld AH; de Vries JP; de Bruin P; Seldenrijk CA; de Kleijn DP; Busser E; Moll FL; Verheijen JH; Virmani R; Pasterkamp G
    Cardiovasc Pathol; 2005; 14(3):126-34. PubMed ID: 15914297
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Can drugs, especially calcium antagonists, bring about regression of atherosclerosis, especially coronary sclerosis?].
    Lichtlen PR
    Schweiz Med Wochenschr; 1991 Dec; 121(49):1807-12. PubMed ID: 1754861
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Surrogate end-points: the case of trials on coronary atherosclerotic plaque regression.
    Marchioli R; Prieto JC; Tognoni G
    Clin Trials Metaanal; 1994 Oct; 29(2-3):139-76. PubMed ID: 10150224
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [High blood pressure and coronary heart disease. Are there new therapeutic options?].
    Motz W
    Herz; 2004 May; 29(3):255-65. PubMed ID: 15167951
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Animal models and potential mechanisms of plaque destabilisation and disruption.
    Ni M; Chen WQ; Zhang Y
    Heart; 2009 Sep; 95(17):1393-8. PubMed ID: 19153105
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of calcium in arteriosclerosis--experimental evaluation of antiarteriosclerotic potencies of Ca antagonists. Study Group for Calcium Antagonism.
    Fleckenstein-Grün G; Thimm F; Frey M; Czirfusz A
    Basic Res Cardiol; 1994; 89 Suppl 1():145-59. PubMed ID: 7945169
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is regression of human atherosclerosis a clinical reality?
    Simons LA
    Med J Aust; 1994 May; 160(9):531-2. PubMed ID: 8164548
    [No Abstract]   [Full Text] [Related]  

  • 39. Anti-atherosclerotic effects of calcium antagonists.
    Holzgreve H; Bürkle B
    J Hypertens Suppl; 1993 Mar; 11(1):S55-9. PubMed ID: 8483024
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Regression of a coronary atheroma. Proof and doubts].
    Ferrières J; Douste-Blazy P; Bernadet P
    Ann Cardiol Angeiol (Paris); 1991 Sep; 40(7):429-36. PubMed ID: 1952775
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.